Skip to content

Miemei lotion combined with clotrimazole vaginal tablets for the treatment of damp heat vulvovaginal candidiasis and its effect on vaginal microecology

Miemei lotion combined with clotrimazole vaginal tablets for the treatment of damp heat vulvovaginal candidiasis and its effect on vaginal microecology

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001237
Enrollment
Unknown
Registered
2026-05-14
Start date
2023-05-09
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulvovaginal candidiasis

Interventions

Control group:Administration of clotrimazole vaginal tablets
Experimental group:Administration of Miemei Lotion combined with Clotrimazole Vaginal Tablets

Sponsors

The First Affiliated Hospital of Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Clinical study results of patients who simultaneously meet the above-mentioned integrated Chinese and Western medicine diagnostic criteria for vulvovaginal candidiasis. (2) Vulvovaginal Candidiasis score < 7; (3) Female patients aged 18–45 years with a history of sexual activity and regular menstrual cycles; (4) No treatment with antibiotics or antifungal agents within the past two weeks; (5) Patients who provided informed consent and were able to cooperate with the treatment and follow-up of this trial.

Exclusion criteria

Exclusion criteria: (1) Patients complicated with other infectious diseases of the vulva and vagina. (2) Patients with a Vulvovaginal Candidiasis score = 7. (3) Patients complicated with diabetes mellitus or other severe primary diseases of the heart, liver, kidney, etc. (4) Patients who meet the age criteria but deny a history of sexual activity. (5) Patients who have taken relevant medications or received treatment for this disease within 2 weeks prior to enrollment. (6) Patients planning for pregnancy, pregnant women, or lactating women. (7) Patients with hypersensitivity to the drugs used in this trial or to multiple drugs.(8) Patients with an unhealthy lifestyle or consumption of spicy and irritating foods during treatment.

Design outcomes

Primary

MeasureTime frame
Time for symptom improvement;Changes in vaginal microecology;Vulvovaginal Candidiasis recurrence rate 1, 2, 3 months after stopping medication;

Secondary

MeasureTime frame
Vulvovaginal Candidiasis score;Therapeutic efficacy of Traditional Chinese Medicine syndromes;

Countries

China

Contacts

Public ContactChen Ping

The First Affiliated Hospital of Henan University of Chinese Medicine

pingping6768@126.com13783589566

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026